Key facts
- This page summarizes Christoph Rudiger Antz's Form 4 filing for Veraxa Biotech AG - Post de-SPAC (VRXA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 Aug 2026, 16:10.
Christoph Rudiger Antz - 27 Aug 2026 Form 4 Insider Report for Veraxa Biotech AG - Post de-SPAC (VRXA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- VRXA
- Reported as of
- 27 Aug 2026
- Net transaction value
- +$7,650
- SEC form
- 4
- Accepted by SEC
- 31 Aug 2026, 16:10:06 UTC
- Prior SEC filing
- 09 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christoph Antz, Chief Executive Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christoph Rudiger Antz filed Form 4 for Veraxa Biotech AG - Post de-SPAC (VRXA) on 31 Aug 2026.
Change
- Previous filing in this sequence was filed on 09 Jun 2026.
- Current net transaction value: +$7,650.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002123284
Primary reporting owner
Antz Christoph Rudiger
- Relationship
- Chief Executive Officer, Director
- Address
- TALACKER 35, ZURICH, SWITZERLAND
- Signature
- /s/ Christoph Antz, Chief Executive Officer
- Signature date
- 31 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRXA
transaction
Ordinary Shares
Purchase
- Transaction value
- $7,650
- Shares
- +5,000
- Change %
- Price
- $1.53
- Shares after
- 5,000
- Date
- 27 Aug 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.